Circulating CD4 +CD25 + regulatory T cells in patients with pancreatic cancer

Pancreas

Volumn 41, Issue 3, 2012, Pages 409-415

  Yamamoto, Tomohisa ^a   Yanagimoto, Hiroaki ^a   Satoi, Sohei ^a   Toyokawa, Hideyoshi ^a   Hirooka, Satoshi ^a   Yamaki, So ^a   Yui, Rintaro ^a   Yamao, Jun ^a   Kim, Songtae ^a   Kwon, A Hon ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

regulatory T cell; resectable pancreatic cancer; risk factor; survival analysis; unresectable pancreatic cancer

Indexed keywords

TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; CANCER INHIBITION; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INOPERABLE CANCER; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PANCREAS RESECTION; PATIENT MONITORING; PERIPHERAL BLOOD MONONUCLEAR CELL; POSTOPERATIVE PERIOD; PREVALENCE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD4; CARCINOMA, PANCREATIC DUCTAL; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; CHI-SQUARE DISTRIBUTION; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PANCREATECTOMY; PANCREATIC NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TIME FACTORS; TREATMENT OUTCOME;

EID: 84859108137     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3182373a66     Document Type: Article

References (31)

1. Edwards BK, Ward E, Kohler BA, et al. Annual report tothe nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116(3):544-573.
2. Hirohashi S, Sobue T, Katanoda K, et al. Cancer Statistics in Japan: Foundation for Promotion of Cancer Research 2007. Tokyo, Japan: The Foundation for Promotion of Cancer Research; 2009:12-13.
3. Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med. 1992;326:455-465.
4. Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma: clinicopathological analysis of 5-year survivors. Ann Surg. 1996;223:273-279. (Pubitemid 26086718)
5. Sperti C, Pasquali C, Piccoli A, et al. Survival after resection for ductal adenocarcinoma of the pancreas. Br J Surg. 1996;83:625-631. (Pubitemid 26163547)
6. Beyer M, Schultze JL. Regulatory Tcells in cancer. Blood. 2006;108(3):804-811.
7. von Bernstorff W, Voss M, Freichel S, et al. Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res. 2001;7:925-932
8. Yanagimoto H, Takai S, Satoi S, et al. Impaired function of circulating dendritic cells in patients with pancreatic cancer. Clin Immunol. 2005;114:52-60. (Pubitemid 39642790)
9. Takahashi K, Toyokawa H, Takai S, et al. Surgical influence of pancreatectomy on the function and count of circulating dendritic cells in patients with pancreatic cancer. Cancer Immunol Immunother. 2006;55:775-784.
10. Yamamoto T, Yanagimoto H, Satoi S, et al. Circulating myeloid dendritic cells as prognostic factors in patients with pancreatic cancer who have undergone surgical resection. J Surg Res. 2010 [Epub ahead of print].
11. Shevach EM. Regulatory Tcells in autoimmunity. Annu Rev Immunol. 2000;18:423-449.
12. Sakaguchi S. Regulatory Tcells: key controllers of immunologic self-tolerance. Cell. 2000;101:455-458.
13. Thomason AM, Shevach EM. Suppressor effector function of cD4+25+immunoregulatory T cells is antigen nonspecific. J Immunol. 2000;164:183-190. (Pubitemid 30012989)
14. Takahashi T, Tagami T, Yamazaki S, et al. Immunologic self-tolerance maintained byCD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2000;192:303-310.
15. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol. 2004;22:531-562. (Pubitemid 38680433)
16. Sasada T, Kimura M, Yoshida Y, et al. CD4+CD25+ regulatory Tcells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer. 2003;98: 1089-1099. (Pubitemid 37022112)
17. Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) Tcells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001;61:4766-4773.
18. Sutmuller RP, van Duivenvoorde LM, van Elsas A, et al. Synergism of cytotoxic Tlymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med. 2001;194:823-832. (Pubitemid 32983017)
19. UICC TNM. Classification of Malignant Tumors. 6th ed. In: Sobin, L, Wittekind C, eds. New York, NY: Wiley-Liss; 2002.
20. Ichihara F, Kono K, Takahashi A, et al. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patient with gastric and esophageal cancers. Clin Cancer Res. 2003;9:4404-4408. (Pubitemid 37248397)
21. Wolf AM, Wolf D, Steurer M, et al. Increase of regulatory Tcells in the peripheral blood of cancer patients. Clin Cancer Res. 2003;9: 606-612. (Pubitemid 36182591)
22. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory Tcells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002;169:2756-2761. (Pubitemid 34921025)
23. Woo EY, Yeh H, Chu CS, et al. Cutting edge: regulatory Tcells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol. 2002;168:4272-4276. (Pubitemid 34441324)
24. Hiraoka N, Onozato K, Kosuge T, et al. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res. 2006;12(18):5423-5434. (Pubitemid 44497257)
25. Hori S, Nomura T, Sakaguchi S. Control of regulatory Tcell development by the transcription factor Foxp3. Science. 2003;299:1057.
26. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4:330-336. (Pubitemid 36432314)
27. Nozoe T, Korenaga D, Ohga T, et al. Suppression of the phytohemagglutinin response to lymphocytes is an independent prognosticator in patients with squamous cell carcinoma of the esophagus. Ann Thorac Surg. 2003;76:260-265. (Pubitemid 36819753)
28. Farinas MC, Rodriguez-Valverde V, Zarrabeitia MT, et al. Contribution of monocytes to the decreased lymphoproliferative response to phytohemagglutinin in patients with lung cancer. Cancer. 1991;68:1279-1284.
29. Bauernhofer T, Kuss I, Henderson B, et al. Preferential apoptosis of cD56dim natural killer cell subset in patients with cancer. Eur J Immunol. 2003;33:119-124. (Pubitemid 36157649)
30. Kono K, Takahashi A, Ichihara F, et al. Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial. Clin Cancer Res. 2002;8:1767-1771. (Pubitemid 34633733)
31. Kono K, Takahashi A, Sugai H, et al. Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T cell responses in patients with gastric cancer. Clin Cancer Res. 2002;8:3394-3400. (Pubitemid 35340713)